New Indication for Pembrolizumab Optimizes Perioperative Treatment Options for NSCLC

New Indication for Pembrolizumab Optimizes Perioperative Treatment Options for NSCLC

With continuous advancements in immunotherapy research, significant progress has been made in improving survival outcomes for patients with non-small cell lung cancer (NSCLC). Recently, based on the results of the KEYNOTE-671 study, the National Medical Products Administration (NMPA) approved the PD-1 inhibitor pembrolizumab for perioperative treatment in patients with resectable stage II, IIIA, and IIIB NSCLC. What is the clinical significance of this newly approved indication for perioperative treatment in NSCLC? What key considerations should clinicians focus on in practice? How will perioperative immunotherapy for NSCLC evolve in the future?
SABCS 2024 | Academician Binghe Xu Presents Latest Research in Oral Presentation and Spotlight Poster at San Antonio

SABCS 2024 | Academician Binghe Xu Presents Latest Research in Oral Presentation and Spotlight Poster at San Antonio

The 47th San Antonio Breast Cancer Symposium (SABCS) successfully concluded in San Antonio, USA. On December 11 (local time), during the second day of the conference, Academician Binghe Xu from the Cancer Hospital Chinese Academy of Medical Sciences delivered a significant presentation in the "General Session 1," unveiling the latest data from the PHILA study (Abstract No.: GS1-03). This nationwide, multicenter randomized controlled trial evaluated the remarkable efficacy of Pyrotinib combined with Trastuzumab and Docetaxel as a first-line treatment for HER2-positive advanced breast cancer. Results showed a striking progression-free survival (PFS) of 22.1 months in the Pyrotinib group, significantly longer than the 10.5 months in the HT group.Oncology Frontier interviewed Academician Binghe Xu on-site to gain in-depth insights into the latest PHILA study data and explore the profound impact of the Pyrotinib combination regimen on the treatment of HER2-positive breast cancer.
SABCS 2024 | Dr. Ting Luo: Four-Year Benefit Analysis of Perioperative Chemotherapy ± Immunotherapy in Triple-Negative Breast Cancer Patients

SABCS 2024 | Dr. Ting Luo: Four-Year Benefit Analysis of Perioperative Chemotherapy ± Immunotherapy in Triple-Negative Breast Cancer Patients

The 47th San Antonio Breast Cancer Symposium (SABCS) successfully took place in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in breast cancer research, SABCS showcased the latest findings, clinical practices, treatment advances, and technological innovations over the past year. Among the presented studies, an oral presentation (GS3-05) analyzed the efficacy of neoadjuvant chemotherapy combined with atezolizumab, followed by adjuvant atezolizumab in triple-negative breast cancer (TNBC) patients. Oncology Frontier invited Dr. Ting Luo from the West China Hospital of Sichuan University to introduce this study and provide expert commentary.
SABCS2024 | Dr. Xiaojia Wang: New PD-1/VEGF Bispecific Antibody and ADC Introduce Novel Strategies, Multiple RWS Provide Key Insights for Comprehensive Breast Cancer Management

SABCS2024 | Dr. Xiaojia Wang: New PD-1/VEGF Bispecific Antibody and ADC Introduce Novel Strategies, Multiple RWS Provide Key Insights for Comprehensive Breast Cancer Management

The 47th San Antonio Breast Cancer Symposium (SABCS) was grandly held from December 10–13, 2024, in San Antonio, USA, showcasing significant global advancements in breast cancer research. During the conference, Dr. Xiaojia Wang from the Cancer Hospital of the University of the Chinese Academy of Sciences (Zhejiang Cancer Hospital) presented several important research findings. These included innovative treatment strategies with the new PD-1/VEGF bispecific antibody Ivosidenib and the novel antibody-drug conjugate (ADC) ARX788. Additionally, multiple real-world studies (RWS) provided valuable clinical insights into intensified adjuvant therapy for early-stage HER2-positive breast cancer, systemic therapy for advanced breast cancer, and breast cancer bone metastases. These contributions amplified the voice of China in breast cancer research at SABCS.Oncology Frontier interviewed Dr. Xiaojia Wang at the conference to share key data from these studies.
Dr. Qiang Liu: Addressing Young Breast Cancer Patients and Exploring Innovations in Diagnosis, Treatment, and Recovery | 2024 Yixian Breast Cancer Conference

Dr. Qiang Liu: Addressing Young Breast Cancer Patients and Exploring Innovations in Diagnosis, Treatment, and Recovery | 2024 Yixian Breast Cancer Conference

The "2024 Yixian Breast Cancer Conference and the Second China Young Breast Cancer Consensus Conference" took place in Guangzhou from December 27 to 28, 2024. The conference explored cutting-edge topics such as the evolving epidemiology of young breast cancer, screening strategies, the impact of genetic mutations, treatment, and recovery approaches. Highlights included the release of the YBCC Consensus on Diagnosis and Treatment (Patient Edition), the China Genetic Mutation Pathogenicity Database, and the Young Breast Cancer Quality of Life Scale. Oncology Frontier interviewed Dr. Qiang Liu, the conference chair from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, to discuss key highlights, the unique epidemiological characteristics of young breast cancer, and future plans for advancing standardized care in this area.
ASH 2024 | Dr. Xiaowen Tang’s Team Pioneers Innovative Transplant Pathways: From Enhanced Preconditioning Strategies to Multi-Targeted CAR-T Sequential Transplantation

ASH 2024 | Dr. Xiaowen Tang’s Team Pioneers Innovative Transplant Pathways: From Enhanced Preconditioning Strategies to Multi-Targeted CAR-T Sequential Transplantation

The 66th Annual Meeting of the American Society of Hematology (ASH), held from December 7–10, 2024, in San Diego, USA, brought together global hematology experts to discuss the latest advancements in the field. Among the highlights of this year’s conference were seven groundbreaking studies from Dr. Xiaowen Tang’s team at The First Affiliated Hospital of Soochow University. These included two oral presentations (O270, O683) and five poster presentations (P3384, P3493, P4197, P4284, P4836). Covering key areas such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), CAR-T cell therapy, and hematopoietic stem cell transplantation (HSCT), the research showcased the team's innovative contributions to hematology. Hematology Frontier interviewed Professor Tang on-site to explore the clinical significance of the two oral presentations, injecting new vitality into the advancement of hematology.
CAHON 2024 Winter Symposium: A New Decade of Excellence Begins, Uniting Global Minds to Shape the Future of Hematology and Oncology

CAHON 2024 Winter Symposium: A New Decade of Excellence Begins, Uniting Global Minds to Shape the Future of Hematology and Oncology

The 66th Annual Meeting of the American Society of Hematology (ASH), the largest and most comprehensive international conference in hematology, successfully took place from December 7 to 10, 2024, in San Diego, USA. This annual event attracts numerous hematology experts and scholars worldwide to exchange ideas and discuss significant breakthroughs in the field. During this year's ASH conference, the Chinese American Hematologist and Oncologist Network (CAHON) held its 2024 Winter Symposium. Experts shared insights, reviewed past accomplishments, and presented cutting-edge advancements in areas ranging from basic research to clinical applications. The event not only fostered academic exchanges and knowledge sharing but also played a pivotal role in advancing the diagnosis and treatment of related diseases while promoting global professional collaboration.
ASH 2024 | Dr. Jun Shi: Landmark Findings in Lymphoma—No Benefit of Auto-HCT in First CR with uMRD in MCL, and R-CHOP-like Regimens Effective for Advanced Relapsed DLBCL

ASH 2024 | Dr. Jun Shi: Landmark Findings in Lymphoma—No Benefit of Auto-HCT in First CR with uMRD in MCL, and R-CHOP-like Regimens Effective for Advanced Relapsed DLBCL

The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, remains the largest and most comprehensive international academic gathering in the field of hematology. Every year, it draws leading experts and scholars from across the globe for in-depth discussions and exchanges on groundbreaking research. This year, the lymphoma field witnessed several pivotal study outcomes. Oncology Frontier - Hematology Frontier invited Dr. Jun Shi from The Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, to provide a detailed analysis and commentary on two highly impactful studies presented during the meeting.
ASH 2024 | Dr. Shenmiao Yang: Advances in Prognostic Factors for Chronic Lymphocytic Leukemia (CLL)

ASH 2024 | Dr. Shenmiao Yang: Advances in Prognostic Factors for Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is highly heterogeneous, with patient survival ranging from a few months to several decades. Therefore, after the diagnosis of CLL, it is particularly important to conduct an accurate and comprehensive prognostic assessment for patients. At the 2024 American Society of Hematology (ASH) Annual Meeting held from December 7th to 10th, some research results on prognostic factors of CLL were announced. "Hematology Frontier" specially invited Dr. Shenmiao Yang from the Peking University Institute of Hematology, to select key studies from the conference and provide insightful commentary, aiming to offer valuable references and insights to colleagues in the field.
ASH 2024 | Dr. Erlie Jiang: Elevated rhTPO Dosing Accelerates Platelet Engraftment and Reduces aGVHD in Allo-HSCT

ASH 2024 | Dr. Erlie Jiang: Elevated rhTPO Dosing Accelerates Platelet Engraftment and Reduces aGVHD in Allo-HSCT

The 66th Annual Meeting of the American Society of Hematology (ASH) took place from December 7–10, 2024, in San Diego, USA. As one of the largest and most prestigious international conferences in the field of hematology, ASH highlighted groundbreaking advancements and new drug development data, showcasing the highest levels of academic research globally. Platelet delay or engraftment failure is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Strategies to accelerate platelet engraftment remain a critical clinical challenge. At this year’s ASH meeting, Dr. Erlie Jiang and his team from the Institute of Hematology & Blood Diseases Hospital (Chinese Academy of Medical Sciences) presented findings from their study (Abstract #266) investigating the effects of elevated recombinant human thrombopoietin (rhTPO) dosing on platelet engraftment in allo-HSCT. Hematology Frontier interviewed Prof. Jiang to explore the research findings and their implications.